Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Dtsch Med Wochenschr ; 146(15): 950-954, 2021 Aug.
Article in German | MEDLINE | ID: covidwho-1338574

ABSTRACT

Acromegaly is a rare but severe disorder which is usually due to an excessive secretion of growth hormone (GH) by a pituitary adenoma. Screening mainly relies on the measurement of insulin-like growth factor 1, and confirmatory diagnostics includes a GH suppression test. As delayed diagnosis results in increased morbidity and mortality, we here discuss recently published suggestions regarding the biochemical work-up of suspected cases and the follow-up of co-morbidities. Moreover, new analytical tools (such as automatic identification of typical facial changes using artificial intelligence) are presented, hopefully allowing for an earlier diagnosis in the future. So far, surgery is still regarded as therapy of first choice. In cases without postoperative remission, a new imaging approach (combining sellar magnetic resonance imaging and position emission tomography) may improve the results of repeated surgery. The pharmaceutical arsenal now includes the first orally available somatostatin analogue, and recent data on possible drug combinations and the outcome of radiotherapy are presented. Finally, special attention is paid to older and pregnant patients, as well as certain considerations during the COVID-19 pandemic (where appropriate diagnosis and management of acromegaly is particularly challenging).


Subject(s)
Acromegaly/diagnosis , Acromegaly/surgery , Acromegaly/diagnostic imaging , Acromegaly/therapy , Adenoma/surgery , Comorbidity , Early Diagnosis , Growth Hormone-Secreting Pituitary Adenoma/surgery , Humans , Prognosis
2.
J Endocrinol Invest ; 44(3): 635-636, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-639909

ABSTRACT

PURPOSE: During the Covid-19 pandemic every hospital has had to change its internal organization. Different institutions have highlighted the risks connected with endoscopic endonasal surgery. The goal of this paper is to illustrate the feasibility of pituitary region surgery during the SARS-CoV-2 pandemic. METHODS: After two negative Covid tests were obtained, three patients with macro GH-secreting tumors, and two patients with micro ACTH-secreting tumors resistant to medical treatment underwent surgery during the pandemic. During the surgery, every patient was treated as if they were positive. RESULTS: Neither operator, nor patient have developed Covid symptoms. The two neurosurgeons performing the operations underwent two Covid swab, which resulted negative. CONCLUSIONS: Pituitary surgery is a high risk non-urgent surgery. However, the method described has so far been effective and is safe for both patients and healthcare providers.


Subject(s)
ACTH-Secreting Pituitary Adenoma/surgery , Adenoma/surgery , COVID-19 , Growth Hormone-Secreting Pituitary Adenoma/surgery , Infection Control , Neurosurgical Procedures/methods , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Testing/standards , Cross Infection/prevention & control , Endoscopy/methods , Endoscopy/standards , Feasibility Studies , Humans , Infection Control/instrumentation , Infection Control/methods , Infection Control/standards , Italy/epidemiology , Neurosurgical Procedures/standards , Nose/surgery , Pandemics , Patient Safety/standards , Patient Selection , Protective Clothing , Protective Devices , Retrospective Studies , SARS-CoV-2/physiology
SELECTION OF CITATIONS
SEARCH DETAIL